Sign up
Pharma Capital

Lifespot Health forms consortium targeting A$3.5bn Australian assisted-living market

The consortium is expected to establish their national infrastructure in the Geelong region
a young man showing a tablet computer to an elderly man on a wheelchair
Aiming to get $20 million from a federal matched funding program

Lifespot Health (ASX:LSH) has formed a consortium to deploy a complete home-assisted living solution in Australia to seniors and those with disabilities and surgical care needs.

The digital health consortium has been formed along with Unisono Pty Ltd and Icon Global.

Importantly, the consortium is aiming to deliver the next level in intelligent management of vulnerable people in the community.

READ: Lifespot Health to deploy its technology in cannabis vaporizers

The integrated product will allow the loop of information on a person’s current health status to be closed and rapid response services to be provided.

The consortium will initially be based in Geelong due to the potential support being offered through the Regional Jobs and Infrastructure Package Grant Program for the Geelong Region.

This is part of a federal matched funding programme offering $220mln nationally, with up to A$20mln on offer in the Geelong region.

The consortium is expected to establish its national infrastructure in the Geelong region if the funding is granted.

Lifespot’s BodyTel System facilitates the management of chronic diseases and assists with the measurement of key vital functions and indicators of these diseases.

Icon Global’s Carelink+ is a market-leading content management system currently used by 140 service providers of health and community services in Australia.

Unisono’s smart home system, Sofihub enables individuals to live more independently by using artificial intelligence to detect anomalies in a resident’s behaviour.

The consortium will work closely with Deakin University, City of Greater Geelong, Microsoft, Telstra and allied health providers including private hospitals and clinical service centres.

Register here to be notified of future LSH Company articles
View full LSH profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.